Nephrotoxicity--what do we know and what don't we know?
- PMID: 21285904
- DOI: 10.1097/MPH.0b013e3181f8cac0
Nephrotoxicity--what do we know and what don't we know?
Abstract
Nephrotoxicity is the development of functional or structural kidney damage after exposure to one or more of a wide variety of drugs, other treatments or exogenous toxins, and may lead to a variety of functional consequences and structural lesions. Nephrotoxicity is important as it may occur in a substantial proportion of children treated with certain drugs and occasionally lead to severe renal impairment that may prevent the delivery of optimal anticancer treatment and/or reduce the quality of life of long-term survivors. This article describes what is currently known about nephrotoxicity occurring in children treated for malignancy by summarizing published information about the clinical characteristics and long-term outcome of, and the risk factors for the development of, ifosfamide and platinum-induced renal toxicity. Published guidelines for the evaluation and surveillance of nephrotoxicity, and the still incomplete understanding of its pathogenesis, are also outlined. Many gaps in our knowledge of nephrotoxicity are highlighted, including the lack of detailed knowledge about its overall incidence and very long-term impact, the nephrotoxic potential of new drugs, the efficacy of surveillance protocols, the relevance of proteinuria as a component of nephrotoxicity, and our current inability to reliably predict or prevent many episodes of nephrotoxicity.
Similar articles
-
Chronic ifosfamide nephrotoxicity in children.Med Pediatr Oncol. 2003 Sep;41(3):190-7. doi: 10.1002/mpo.10336. Med Pediatr Oncol. 2003. PMID: 12868118 Review.
-
Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.J Clin Pharmacol. 1999 May;39(5):454-61. J Clin Pharmacol. 1999. PMID: 10234592
-
Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.Pediatr Nephrol. 2018 Feb;33(2):215-225. doi: 10.1007/s00467-017-3662-z. Epub 2017 Apr 22. Pediatr Nephrol. 2018. PMID: 28434047 Free PMC article. Review.
-
[Renal complications of anti-cancer chemotherapy].Pathol Biol (Paris). 1986 Nov;34(9):1013-28. Pathol Biol (Paris). 1986. PMID: 3543812 Review. French.
-
Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.Eur J Cancer. 2009 Dec;45(18):3213-9. doi: 10.1016/j.ejca.2009.06.032. Epub 2009 Oct 21. Eur J Cancer. 2009. PMID: 19850470
Cited by
-
Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors.Clin Genitourin Cancer. 2015 Oct;13(5):453-60. doi: 10.1016/j.clgc.2015.05.003. Epub 2015 May 16. Clin Genitourin Cancer. 2015. PMID: 26072101 Free PMC article. Clinical Trial.
-
Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma.Pediatr Blood Cancer. 2012 Oct;59(4):611-6. doi: 10.1002/pbc.24031. Epub 2011 Dec 16. Pediatr Blood Cancer. 2012. PMID: 22180320 Free PMC article.
-
Long-term nephrotoxicity in adult survivors of childhood cancer.Clin J Am Soc Nephrol. 2013 Jun;8(6):922-9. doi: 10.2215/CJN.09980912. Epub 2013 Feb 14. Clin J Am Soc Nephrol. 2013. PMID: 23411430 Free PMC article.
-
The growing pains of ifosfamide.Clin Kidney J. 2020 Apr 17;13(4):500-503. doi: 10.1093/ckj/sfaa017. eCollection 2020 Aug. Clin Kidney J. 2020. PMID: 32897272 Free PMC article.
-
Partial Fanconi Syndrome Induced by Ifosfamide.Cureus. 2019 Jan 23;11(1):e3947. doi: 10.7759/cureus.3947. Cureus. 2019. PMID: 30937245 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical